As Dr. George had pointed out, it is interesting to note that Nivolumab can lead to a tumor flare phenomenon making RECIST criteria difficult to interpret when determining treatment response. Dr. Quinn also made a good point about the duration of treatment when we observe lesions increasing in size on scans.
Given these potential confounding factors, how does one assess for treatment failure in patients with metastatic RCC? How long should we maintain patients on treatment before calling it a failure? Would the authors or experts elaborate on this point?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.